Some embodiments provided herein relate to methods, systems and kits for providing consistent intracoronary administration of a biologic to subjects having diverse coronary anatomies. In some embodiments, the biologic is an adeno-associated virus serotype 1 (AAV1) vector encoding sarcoplasmic/endoplasmic reticulum ATPase 2a (SERCA2a) protein.

An antibiotic-eluting article for implantation into a mammalian subject, produced by an additive manufacturing process wherein a polymeric material is concurrently deposited with a selected antibiotic. The additive manufacturing process is a fused deposition modeling process. The antibiotic-eluting article may be temporary or permanent orthopaedic skeletal component, an orthopaedic articulating joint replacement component, and/or an external hard-shell casing for an implantable device. One or more bone-growth-promoting compositions may be concurrently deposited with the polymeric material. The implantable device may be a cardiac pacemaker, a spinal cord stimulator, a neurostimulation system, an intrathecal drug pump for delivery of medicants into the spinal fluid, and infusion pump for delivery of chemotherapeutics and or anti-spasmodics, an insulin pump, an osmotic pump, and a heparin pump.

Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiologica condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.

The present invention is directed to novel non-woven fabrics containing growth and differentiation factor proteins. Said fabrics are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues. Furthermore, the invention provides wound dressings, pads or implants comprising the novel non-woven fabrics.

Methods and compositions for promoting wound healing in a patient by administering a collagen-binding synthetic peptidoglycan to the patient are described. Additionally, methods and compositions are described for decreasing scar formation in a patient by administering a collagen-binding synthetic peptidoglycan to the patient.

Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.

The present invention refers to compositions comprising recombinant biopolymers made of combinations of monomers of the type “Elastin-like recombinamers” (ELR), monomers comprising the “silk” sequence and/or monomers comprising the HLF sequence that belongs to a natural class of proteins named zippers. Said compositions are useful as bio-ink for 3D printing. Furthermore, the present invention also refers to methods for obtaining the composition of the invention, as well as the 3D biomaterial and to the different uses of the composition and the obtained biomaterial.

Medical devices and methods including polymers having biologically active agents therein are disclosed. The medical devices can be useful as implantable devices such as orthopedic implants.

Systems and methods for purification and concentration of autologous alpha-2 macroglobulin (A2M) from whole blood and or recombinant A2M are provided. Also provided are methods of treating wounds with A2M. Methods for utilizing A2M in combination with other treatments (e.g., platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and/or to prolong the half-life of the protein for treating wounds.

Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.